623577-33-3

Usage

Uses

Used in Pharmaceutical Industry:
5-(4-Fluoro-phenyl)-1-methyl-1,2-dihydropyrazol-3-one is utilized as a potential pharmaceutical agent for its possible biological activities. The presence of the 4-fluoro-phenyl and methyl groups may confer specific binding affinities to targeted receptors or enzymes, suggesting its use in the development of drugs for various therapeutic areas. However, additional research and testing are necessary to confirm its efficacy and safety in clinical settings.
Due to the lack of specific application details in the provided materials, the uses listed above are based on the general potential of the compound's structure and the common practices in the pharmaceutical industry. Further information on the compound's pharmacological properties would allow for more detailed and specific applications to be identified.

Upstream product

• 42122-44-1 methyl 3-(4-fluorophenyl)propiolate 
• 60-34-4 methylhydrazine 
• 352-34-1 4-fluoro-1-iodobenzene 
• 1736-31-8 ethyl 3-(4-fluorophenyl)propiolate 
• 2928-14-5 3-(4-Fluorophenyl)propionic acid,methyl ester 
• 63131-29-3 methyl 4-fluorobenzoyl acetate 

Downstream Products

• 699010-08-7 1-methyl-3⁽⁵⁾-(4-fluorophenyl)-pyrazole nonaflate 
• 623577-34-4 trifluoromethanesulfonic acid 5-(4-fluorophenyl)-1-methyl-1H-pyrazol-3-yl ester 

Relevant academic research and scientific papers

Consecutive Three-Component Coupling-Addition Synthesis of β-Amino Enoates and 3-Hydroxypyrazoles via Ethyl 3-Arylpropiolates

Two consecutive three-component syntheses furnishing β-amino enoates or 3-hydroxypyrazoles based upon the Sonogashira alkynylation of aryl iodides and ethyl propiolate were established in mostly excellent yields. The ethyl 3-arylpropiolate intermediates are Michael systems which are suited for concatenation with conjugate addition or cyclocondensation giving access to libraries of 21 different β-amino enoates and 17 different 3-hydroxypyrazoles. The rotational barrier of β-pyrrolidino enoates was assessed by studying the coalescence of pyrrolidinyl protons in VT-NMR spectra of electronically different substituted derivatives showing that the electronic substituent effect on the aryl group does not affect the height of the rotational barrier. This indicates that the substituents are essentially oriented orthogonally to the plane of the β-pyrrolidino enoates.

Gamma-secretase inhibitors

Compounds of formula I: inhibit gamma-secretase and hence find use in treatment of Alzheimer's disease.

PYRAZOLE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS USEFUL IN THE TREATMENT OF ALZHEIMER’S DISEASE

The compounds of formula (I): inhibit gamma-secretase and hence are of utility in the treatment or prevention of Alzheimer's disease.

SULFONAMIDES, SULFAMATES AND SULFAMIDES AS GAMMA-SECRETASE INHIBITORS

Compounds of formula I inhibit the processing of APP by gamma-secretase, and hence are useful in treating or preventing Alzheimer's disease.

Regioselective rapid analogue syntheses of 1-methyl-3,5-diarylpyrazoles via palladium-catalysed coupling to 3(5)-pyrazolyl nonaflates

Regioselective rapid analogue syntheses of 1-methyl-3,5-diarylpyrazoles were developed, based on Pd-catalysed couplings to 1-methyl-3(5)-arylpyrazole nonaflates, which offered an advantage in hydrolytic stability over the corresponding triflates. The new bifunctional reagent 1-methyl-3-bromo-pyrazol- 5-yl nonaflate underwent highly chemoselective Pd-catalysed couplings to the nonaflate, followed by Suzuki couplings to the bromide, allowing sequential, regioselective introduction of the two aryl substituents.

HETEROARYL SUBSTITUTED SPIROCYCLIC SULFAMIDES FOR INHIBITION OF GAMMA SECRETASE

Compounds of formula I are disclosed: in which X is a 5-membered heteroaryl ring and R is as defined herein. The compounds are inhibitors of the processing of APP by gamma-secretase, and hence are useful in the treatment or prevention of Alzheimer's disease.